©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Ophthalmol. May 12, 2015; 5(2): 73-79
Published online May 12, 2015. doi: 10.5318/wjo.v5.i2.73
Published online May 12, 2015. doi: 10.5318/wjo.v5.i2.73
Current understanding and management of aggressive posterior retinopathy of prematurity
Christine M Pulido, Polly A Quiram, VitreoRetinal Surgery, P.A., Minneapolis, MN 55435, United States
Author contributions: Quiram PA and Pulido CM equally contributed to this paper.
Conflict-of-interest: The authors declare that they have no competing interests.
Correspondence to: Polly A Quiram, MD, PhD, VitreoRetinal Surgery, P.A., 7760 France Ave S, Suite 310, Minneapolis, MN 55435, United States. pollyquiram@yahoo.com
Telephone: +1-952-9291131
Received: November 29, 2014
Peer-review started: November 29, 2014
First decision: December 12, 2014
Revised: January 12, 2015
Accepted: March 4, 2015
Article in press: March 5, 2015
Published online: May 12, 2015
Processing time: 171 Days and 6.7 Hours
Peer-review started: November 29, 2014
First decision: December 12, 2014
Revised: January 12, 2015
Accepted: March 4, 2015
Article in press: March 5, 2015
Published online: May 12, 2015
Processing time: 171 Days and 6.7 Hours
Core Tip
Core tip: Neonates with aggressive posterior retinopathy of prematurity often have unfavorable visual outcomes due to the aggressive and destructive nature of the disease. Treatment options, including laser and anti-vascular endothelial growth factor therapy can change the course of the disease, but both with potential side effects. Case studies and recommendations regarding the management of these complicated cases are reviewed.